ImmunityBio 
Welcome,         Profile    Billing    Logout  
 25 Products   173 Diseases  25 Products   61 Trials   2057 News 
69 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ganitumab (AMG 479) / Takeda, ImmunityBio
AEWS1221, NCT02306161: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting
3
312
Canada, US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Ganitumab, AMG 479, AMG-479, AMG479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Therapeutic Surgical Procedure, Vincristine, LCR, Leurocristine, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
03/21
09/25
NCT04129151: Palbociclib + Ganitumab In Ewing Sarcoma

Terminated
2
10
US
Palbociclib, Ibrance®, Ganitumab, AMG-479
Dana-Farber Cancer Institute, 1 Million 4 Anna Foundation, Carson Sarcoma Foundation, Teaming up to Fight Childhood Cancer, ChemoWarrior: the eli sidler foundation, i-ROK Foundation, Rutledge Cancer Foundation, Alan B. Slifka Foundation
Ewing Sarcoma, Ewing's Sarcoma Recurrent
12/22
12/22
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT03029481: Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

No Longer Available
N/A
NA
Ganitumab, AMG 479
Jonsson Comprehensive Cancer Center, NantCell, Inc.
Ewing Sarcoma
 
 
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting
N/A
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
GI-4000 / ImmunityBio
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
1/2
2
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
04/19
08/19
QUILT-3.067, NCT03387085: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated
1/2
9
US
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
ImmunityBio, Inc.
Triple Negative Breast Cancer
09/20
01/24
aldoxorubicin (INNO-206) / LadRx
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
10/25
10/25
NCT02570412: Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

No Longer Available
N/A
US
aldoxorubicin
CytRx
Sarcoma
 
 
Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Randomized study of Genexol-PM combined with Cisplatin in advanced NSCLC, ChiCTR-IPR-15006252: A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
426
 
Genexol-PM+Cisplatin ;Paclitaxel Injection + Cisplatin
Guangdong General Hospital; Shanghai Chest Hospital; Jiangsu Cancer Hospital; Shanghai Yizhong Bio-technology Co., Ltd, self-financing
Non-Small Cell Lung Cancer(NSCLC)
 
 
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
ChiCTR-ONC-14005123: Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced tomors

Completed
1
12
 
Genexol-PM
Jiangsu Cancer Hospital; None, self-financing
advanced tumor
 
 
NCT06936787: An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

Recruiting
1
21
RoW
IGT001
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Retinitis Pigmentosa
12/25
12/27
NCT05300828: Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

Completed
N/A
600
RoW
Genexl PM
Seoul National University Hospital, Samyang Biopharmaceuticals Corporation
Ovarian Cancer
04/22
12/22
ensituximab (NEO-102) / Precision Biologics
NCT01714453: NPC-1C With Gemcitabine for Advanced Pancreatic Cancer

Not yet recruiting
1/2
18
US
NPC-1C Antibody, Gemcitabine
National Cancer Institute (NCI), Precision Biologics Oncology, Inc.
Metastatic Pancreatic Neoplasms
10/14
10/14
ETBX-011 / ImmunityBio
NCT04247282: Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Completed
1/2
21
US
M7824, bintrafusp alfa, N803, Anktiva, TriAd vaccine, ETBX-011, ETBX-051 & ETBX-061
National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Neoplasms
08/21
06/23
NEO-201 / Precision Biologics
QUILT-3.017, NCT03476681: Study of NEO-201 in Solid Tumors Expansion Cohorts

Recruiting
1/2
121
US
NEO-201 in combination with pembrolizumab, IHC screening for NEO-201 target
Precision Biologics, Inc
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
01/28
01/29
Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
QUILT2023, NCT03520686: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Active, not recruiting
3
1538
US
N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, Pembrolizumab, Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
ImmunityBio, Inc.
Non Small Cell Lung Cancer
10/25
04/26
NCT06745908: ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
460
US
N-803, Tislelizumab, Docetaxel
ImmunityBio, Inc.
NSCLC Stage IV
09/28
01/29
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
QUILT-505, NCT06239220: PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Recruiting
2
25
US
PD-L1 t-haNK, NK-92, Cetuximab, Erbitux, N-803, Interleukin-15, IL-15, Anktiva
Glenn J. Hanna, ImmunityBio, Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
07/25
01/27
QUILT-3.055, NCT03228667: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Checkmark For relapsed NSCLC based on QUILT-3.055 study
Jan 2021 - Jan 2021: For relapsed NSCLC based on QUILT-3.055 study
Recruiting
2
40
US
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
ImmunityBio, Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
08/29
12/30
NCT05445882: N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Withdrawn
2
28
US
Bintrafusp alfa, N-803, BN-Brachyury
National Cancer Institute (NCI)
Castration Resistant Prostate Cancer
04/24
04/24
NCT04505501: Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection

Active, not recruiting
2
14
RoW
N-803, ALT-803
Thai Red Cross AIDS Research Centre, Henry M. Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research (WRAIR)
HIV/AIDS
06/25
06/25
NCT04847466: Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Recruiting
2
55
US
N-803, Pembrolizumab, PD-L1 t-haNK
National Cancer Institute (NCI)
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
01/27
12/27
NCT06710288: A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting
2
20
US
Gemcitabine, gemcitabine hydrocholoride, Gemzar, N-803, M-CENK, Autologous Memory Cytokine Enriched Natural Killer
ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer
05/27
05/27
NCT06829823: Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Not yet recruiting
2
20
NA
N-803 and BCG, BCG, N-803, Bacillus Calmette-Guérin, N-803 and Gemcitabine, Gemcitabine, Gemzar
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer (NMIBC)
05/26
05/29
NCT06765902: Immunotherapy Before and After Surgery

Not yet recruiting
2
20
NA
N-803, ETBX-071, M-CENK
ImmunityBio, Inc.
High-risk Prostate Cancer
01/31
06/31
NCT06765954: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Not yet recruiting
2
20
NA
N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells), External Beam Radiation Therapy (EBRT), Androgen Deprivation Therapy (ADT), Post-radiation immunotherapy
ImmunityBio, Inc.
High-risk Prostate Cancer
01/31
06/31
NCT06161545: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
40
US
N-803, pembrolizumab, PD-L1 t-haNK cells
National Cancer Institute (NCI)
Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
12/25
12/27
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
07/26
07/26
NCT05419011: Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Active, not recruiting
2
186
US
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5, Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5, Tri Ad5, Tri-Ad5, TriAd5, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
07/27
01/28
NCT06061809: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Recruiting
2
20
US
Bevacizumab, Avastin, PD-L1 t-haNK, N-803, ALT-803, Anktiva
ImmunityBio, Inc.
Glioblastoma
12/29
12/30
QUILT-3.058, NCT04927884: A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Terminated
1/2
3
US
N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide
ImmunityBio, Inc.
Advanced Triple Negative Breast Cancer
09/22
12/22
NCT02523469: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
1/2
58
US
ALT-803, Nivolumab, OPDIVO
Medical University of South Carolina, Altor BioScience
Non-small Cell Lung Cancer
02/23
02/23
QuEST1, NCT03493945: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat

Completed
1/2
59
US
M7824, Bintrafusp alfa, N-803, Anktiva, MVA-BN-Brachyury, modified vaccinia Ankara Bavarian Nordic Brachyury, FPV-Brachyury, Fowlpox Virus Brachyury, Epacadostat, IDO1, Acetaminophen, Tylenol, Ofirmev, FeverAll, Ibuprofen, Advil, Advil Migraine, Naproxen, Aleve, Naprosyn, Anaprox DS, Benadryl, Diphenhydramine, EKG, Electrocardiogram, Bone scan, Bone scintigraphy, CT chest, abdomen and pelvis, Computed tomography chest, abdomen and pelvis, MRI, Magnetic resonance imaging
National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
10/24
10/24
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
QUILT 502, NCT06253494: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Recruiting
1/2
60
US
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
National Cancer Institute (NCI)
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
12/26
12/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT05642195: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Suspended
1/2
30
US
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
12/33
12/35
NCT05981131: Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1b
6
US
N803 plus Bacillus Calmette-Guerin (BCG)
ImmunityBio, Inc.
Non Muscle Invasive Bladder Cancer
08/33
08/33
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Completed
1
14
US
Natural Killer (NK) Cells, ALT803, Cytokine
Brenda Cooper, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
06/21
02/23
NCT04385849: Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Terminated
1
1
US
N-803, Saline
ImmunityBio, Inc.
COVID-19
07/20
07/20
NCT04290546: CIML NK Cell in Head & Neck Cancer

Completed
1
11
US
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, cytokine induced memory-like natural killer, Ipilimumab, CTLA-4 inhibitor, Cetuximab, EGFR inhibitor
Dana-Farber Cancer Institute, Altor BioScience, Bristol-Myers Squibb, Miltenyi Biomedicine GmbH
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
09/24
12/24
NCT06040918: Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Completed
1
10
US
N-803
ImmunityBio, Inc.
Healthy Subjects
09/24
09/24
QUILT-3.076, NCT04898543: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
50
US
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
ImmunityBio, Inc.
Metastatic Solid Tumor
05/25
05/25
NCT06318871: Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Recruiting
1
10
US
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, NK Cells, Interleukin-2 (IL-2)
Dana-Farber Cancer Institute, Kidney Cancer Association
Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
12/25
05/30
NCT05618925: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting
1
20
US
N803, Anktiva, CD19t-haNK suspension, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Rituximab, Rituxan
ImmunityBio, Inc.
Non Hodgkin's Lymphoma Refractory/Relapsed
03/26
03/27
NCT06321484: Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Recruiting
1
18
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin 2
Dana-Farber Cancer Institute, ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent
11/26
10/31
RV582, NCT05769569: Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Withdrawn
1
35
RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGDM1400LS, N-803, Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120, ALFQ, Antiretroviral Therapy (ART)
Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, Janssen Vaccines & Prevention B.V.
HIV-1-infection
07/25
07/25
CARMEN-803, NCT07049432: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Not yet recruiting
1
13
US
N803
University of Utah, ImmunityBio, Inc.
B-cell Non Hodgkin Lymphoma
09/28
09/29
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruiting
1
118
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
NCT05245292: 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Active, not recruiting
1
28
US
3BNC117-LS, broadly neutralizing antibody, monoclonal antibody, 10-1074-LS, N803, IL-15 superagonist complex
Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania
Human Immunodeficiency Virus
12/25
12/25
NCT06956547: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Available
N/A
US
nogapendekin-alfa inbakicept, NAI, N-803
ImmunityBio, Inc.
Lymphopenia
 
 
YE-NEO 001 / ImmunityBio
QUILT-2.025, NCT03552718: NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Active, not recruiting
1
16
US
YE-NEO-001, YE-NEO-001 Injectable Suspension
NantBioScience, Inc.
Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
07/25
12/25
PD-L1.t-haNK / ImmunityBio
QUILT 3.064, NCT04050709: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Active, not recruiting
1
16
US
PD-L1 t-haNK
ImmunityBio, Inc.
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
10/24
12/24
HER2 t-haNK / ImmunityBio
CAR2BRAIN, NCT03383978: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting
1
42
Europe
NK-92/5.28.z, Ezabenlimab
Johann Wolfgang Goethe University Hospital, DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, LOEWE Center Frankfurt Cancer Institute, German Cancer Research Center
Glioblastoma
12/25
06/26
bone marrow-derived mesenchymal stem cells / Be The Match BioTherapies, ImmunityBio
NCT04397796: Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

Terminated
1
4
US
BM-Allo.MSC, Placebo
ImmunityBio, Inc.
COVID
09/20
09/20
Ad5-Covid-S/N / ImmunityBio
NCT06022224: A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Terminated
2/3
35
US
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
ImmunityBio, Inc.
COVID-19
06/22
07/23
NCT04591717: COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

Completed
1b
34
US
hAd5-S-Fusion+N-ETSD vaccine
ImmunityBio, Inc.
COVID-19
04/22
01/23
NCT04732468: COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Terminated
1
28
US
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
ImmunityBio, Inc.
Covid19
07/22
01/23
NCT04710303: COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults

Completed
1
41
RoW
hAd5-S-Fusion+N-ETSD vaccine
ImmunityBio, Inc.
Covid19
08/22
08/22
CD19.t-haNK / ImmunityBio
NCT06334991: Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma

Recruiting
1
10
RoW
CD19 t-haNK, Rituximab
ImmunityBio, Inc.
Non-Hodgkin Lymphoma Refractory/ Relapsed
03/26
03/27
HCW9218 / HCW Biologics, ImmunityBio
NCT05145569: Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Withdrawn
2
33
NA
Carboplatin AUC 5 and paclitaxel, Carbo/Taxol, HCW9218
Haider Mahdi, HCW Biologics
Ovarian Cancer
05/26
01/28
NCT05304936: HCW9218 for Advanced Pancreatic Cancer

Active, not recruiting
1/2
60
US
HCW9218
ImmunityBio, Inc.
Advanced Pancreatic Carcinoma
01/25
02/25
NCT05322408: HCW9218 in Select Advanced Solid Tumors

Active, not recruiting
1
18
US
HCW9218, Monotherapy
Masonic Cancer Center, University of Minnesota
Solid Tumor
01/25
02/26
AAHI-SC2 Vaccine / ImmunityBio
NCT05370040: THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Terminated
1/2
60
RoW
AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine
ImmunityBio, Inc.
COVID-19
03/24
03/24
AAHI-SC3 Vaccine / ImmunityBio
No trials found
N-812 / ImmunityBio
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ganitumab (AMG 479) / Takeda, ImmunityBio
AEWS1221, NCT02306161: Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active, not recruiting
3
312
Canada, US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Etoposide Phosphate, Etopophos, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Ganitumab, AMG 479, AMG-479, AMG479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Therapeutic Surgical Procedure, Vincristine, LCR, Leurocristine, VCR, Vincrystine, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow, Metastatic Malignant Neoplasm in the Lung, Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
03/21
09/25
NCT04129151: Palbociclib + Ganitumab In Ewing Sarcoma

Terminated
2
10
US
Palbociclib, Ibrance®, Ganitumab, AMG-479
Dana-Farber Cancer Institute, 1 Million 4 Anna Foundation, Carson Sarcoma Foundation, Teaming up to Fight Childhood Cancer, ChemoWarrior: the eli sidler foundation, i-ROK Foundation, Rutledge Cancer Foundation, Alan B. Slifka Foundation
Ewing Sarcoma, Ewing's Sarcoma Recurrent
12/22
12/22
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
NCT03029481: Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma

No Longer Available
N/A
NA
Ganitumab, AMG 479
Jonsson Comprehensive Cancer Center, NantCell, Inc.
Ewing Sarcoma
 
 
NCT04199026: Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Recruiting
N/A
20
US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Drug Delivery Microdevice, Microdevice, Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Ganitumab, AMG 479, Anti-IGF-1R Human Monoclonal Antibody AMG-479, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Pazopanib, GW786034, Polyethylene Glycol, Glycol, polyethylene, PEG, Poly(oxyethylene), Polyethylene Glycol 400, Polyethylene Glycol 8000, POLYETHYLENE GLYCOL, UNSPECIFIED, Polyethylene Oxide, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel, Therapeutic Conventional Surgery, Vincristine, LEUROCRISTINE, VCR, Vincrystine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
12/25
12/25
GI-4000 / ImmunityBio
QUILT-3.071, NCT03563157: QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
1/2
2
US
Aldoxorubicin Hydrochloride, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Capecitabine, Cetuximab, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Nab-paclitaxel, Oxaliplatin, Regorafenib, SBRT
ImmunityBio, Inc.
Colorectal Cancer Metastatic, mCRC
04/19
08/19
QUILT-3.067, NCT03387085: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Terminated
1/2
9
US
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
ImmunityBio, Inc.
Triple Negative Breast Cancer
09/20
01/24
aldoxorubicin (INNO-206) / LadRx
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
10/25
10/25
NCT02570412: Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy

No Longer Available
N/A
US
aldoxorubicin
CytRx
Sarcoma
 
 
Cynviloq (paclitaxel polymeric micelle formulation) / Sorrento, Samyang Group, ImmunityBio
Randomized study of Genexol-PM combined with Cisplatin in advanced NSCLC, ChiCTR-IPR-15006252: A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
426
 
Genexol-PM+Cisplatin ;Paclitaxel Injection + Cisplatin
Guangdong General Hospital; Shanghai Chest Hospital; Jiangsu Cancer Hospital; Shanghai Yizhong Bio-technology Co., Ltd, self-financing
Non-Small Cell Lung Cancer(NSCLC)
 
 
NCT07009925: Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.

Not yet recruiting
2
38
NA
Ivonescimab 20mg/kg intravenous every 3 weeks, paclitaxel polymeric micelles ≤300mg/㎡intravenous every 3 weeks, platinum intravenous every 3 weeks
Jiangsu Cancer Institute & Hospital
Squamous Cell Lung Cancer
05/27
05/28
ChiCTR-ONC-14005123: Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced tomors

Completed
1
12
 
Genexol-PM
Jiangsu Cancer Hospital; None, self-financing
advanced tumor
 
 
NCT06936787: An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa

Recruiting
1
21
RoW
IGT001
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Retinitis Pigmentosa
12/25
12/27
NCT05300828: Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

Completed
N/A
600
RoW
Genexl PM
Seoul National University Hospital, Samyang Biopharmaceuticals Corporation
Ovarian Cancer
04/22
12/22
ensituximab (NEO-102) / Precision Biologics
NCT01714453: NPC-1C With Gemcitabine for Advanced Pancreatic Cancer

Not yet recruiting
1/2
18
US
NPC-1C Antibody, Gemcitabine
National Cancer Institute (NCI), Precision Biologics Oncology, Inc.
Metastatic Pancreatic Neoplasms
10/14
10/14
ETBX-011 / ImmunityBio
NCT04247282: Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

Completed
1/2
21
US
M7824, bintrafusp alfa, N803, Anktiva, TriAd vaccine, ETBX-011, ETBX-051 & ETBX-061
National Cancer Institute (NCI)
Head and Neck Cancer, Head and Neck Neoplasms
08/21
06/23
NEO-201 / Precision Biologics
QUILT-3.017, NCT03476681: Study of NEO-201 in Solid Tumors Expansion Cohorts

Recruiting
1/2
121
US
NEO-201 in combination with pembrolizumab, IHC screening for NEO-201 target
Precision Biologics, Inc
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
01/28
01/29
Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
QUILT2023, NCT03520686: QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Active, not recruiting
3
1538
US
N-803 + Pembrolizumab, N-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab, N-803 + Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, Pembrolizumab, Carboplatin + Nab-paclitaxel or Paclitaxel + Pembrolizumab, Cisplatin or Carboplatin + Pembrolizumab + Pemetrexed, N-803 + Carboplatin + Nab-paclitaxel + Ipilimumab + Nivolumab
ImmunityBio, Inc.
Non Small Cell Lung Cancer
10/25
04/26
NCT06745908: ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
460
US
N-803, Tislelizumab, Docetaxel
ImmunityBio, Inc.
NSCLC Stage IV
09/28
01/29
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
10/24
03/29
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
NCT04491955: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Completed
2
32
US
CV301, MSB0011359C, N-803, NHS-IL12
National Cancer Institute (NCI)
Small Bowel Cancers, Colorectal Cancers
10/22
08/24
QUILT-505, NCT06239220: PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

Recruiting
2
25
US
PD-L1 t-haNK, NK-92, Cetuximab, Erbitux, N-803, Interleukin-15, IL-15, Anktiva
Glenn J. Hanna, ImmunityBio, Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
07/25
01/27
QUILT-3.055, NCT03228667: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Checkmark For relapsed NSCLC based on QUILT-3.055 study
Jan 2021 - Jan 2021: For relapsed NSCLC based on QUILT-3.055 study
Recruiting
2
40
US
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab
ImmunityBio, Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
08/29
12/30
NCT05445882: N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Withdrawn
2
28
US
Bintrafusp alfa, N-803, BN-Brachyury
National Cancer Institute (NCI)
Castration Resistant Prostate Cancer
04/24
04/24
NCT04505501: Reducing HIV Persistence in Lymph Nodes by Interleukin-15 (IL-15) Receptor Super-agonist (N-803) in Acute HIV Infection

Active, not recruiting
2
14
RoW
N-803, ALT-803
Thai Red Cross AIDS Research Centre, Henry M. Jackson Foundation for the Advancement of Military Medicine, Walter Reed Army Institute of Research (WRAIR)
HIV/AIDS
06/25
06/25
NCT04847466: Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer

Recruiting
2
55
US
N-803, Pembrolizumab, PD-L1 t-haNK
National Cancer Institute (NCI)
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC
01/27
12/27
NCT06710288: A Phase 2, Open-label, Single-arm Study of Autologous M-CENK Adoptive Cell Therapy and N-803 (IL-15 Superagonist) in Combination with Gemcitabine in Participants with Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting
2
20
US
Gemcitabine, gemcitabine hydrocholoride, Gemzar, N-803, M-CENK, Autologous Memory Cytokine Enriched Natural Killer
ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer
05/27
05/27
NCT06829823: Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Not yet recruiting
2
20
NA
N-803 and BCG, BCG, N-803, Bacillus Calmette-Guérin, N-803 and Gemcitabine, Gemcitabine, Gemzar
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer (NMIBC)
05/26
05/29
NCT06765902: Immunotherapy Before and After Surgery

Not yet recruiting
2
20
NA
N-803, ETBX-071, M-CENK
ImmunityBio, Inc.
High-risk Prostate Cancer
01/31
06/31
NCT06765954: Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

Not yet recruiting
2
20
NA
N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells), External Beam Radiation Therapy (EBRT), Androgen Deprivation Therapy (ADT), Post-radiation immunotherapy
ImmunityBio, Inc.
High-risk Prostate Cancer
01/31
06/31
NCT06161545: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Not yet recruiting
2
40
US
N-803, pembrolizumab, PD-L1 t-haNK cells
National Cancer Institute (NCI)
Stage II Squamous Cell Carcinoma of the Head and Neck, Stage III Squamous Cell Carcinoma of the Head and Neck, Stage IV Squamous Cell Carcinoma of the Head and Neck
12/25
12/27
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
07/26
07/26
NCT05419011: Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Active, not recruiting
2
186
US
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Ad5-CEA/Ad5-MUC1/Ad5-Brachyury Vaccine Tri-Ad5, Adenoviral CEA/MUC1/Brachyury Vaccine Tri-Ad5, Tri Ad5, Tri-Ad5, TriAd5, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
07/27
01/28
NCT06061809: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Recruiting
2
20
US
Bevacizumab, Avastin, PD-L1 t-haNK, N-803, ALT-803, Anktiva
ImmunityBio, Inc.
Glioblastoma
12/29
12/30
QUILT-3.058, NCT04927884: A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Terminated
1/2
3
US
N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy, Cyclophosphamide
ImmunityBio, Inc.
Advanced Triple Negative Breast Cancer
09/22
12/22
NCT02523469: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
1/2
58
US
ALT-803, Nivolumab, OPDIVO
Medical University of South Carolina, Altor BioScience
Non-small Cell Lung Cancer
02/23
02/23
QuEST1, NCT03493945: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat

Completed
1/2
59
US
M7824, Bintrafusp alfa, N-803, Anktiva, MVA-BN-Brachyury, modified vaccinia Ankara Bavarian Nordic Brachyury, FPV-Brachyury, Fowlpox Virus Brachyury, Epacadostat, IDO1, Acetaminophen, Tylenol, Ofirmev, FeverAll, Ibuprofen, Advil, Advil Migraine, Naproxen, Aleve, Naprosyn, Anaprox DS, Benadryl, Diphenhydramine, EKG, Electrocardiogram, Bone scan, Bone scintigraphy, CT chest, abdomen and pelvis, Computed tomography chest, abdomen and pelvis, MRI, Magnetic resonance imaging
National Cancer Institute (NCI)
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
10/24
10/24
NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Recruiting
1/2
60
US
Retifanlimab, Therapeutic CEA, Brachyury and MUC1 TriAdeno Vaccine Platform, N-803, SX-682
National Cancer Institute (NCI)
Metastatic Colorectal Cancer
10/25
10/28
QUILT 502, NCT06253494: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

Recruiting
1/2
60
US
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
National Cancer Institute (NCI)
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
12/26
12/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
NCT05642195: Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Suspended
1/2
30
US
Montanide (Registered Trademark) ISA-51 VG Adjuvant, H1299 Cell Lysates, N-803, Ventana PD-L1 (SP263 or SP142) assay
National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinomas
12/33
12/35
NCT05981131: Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1b
6
US
N803 plus Bacillus Calmette-Guerin (BCG)
ImmunityBio, Inc.
Non Muscle Invasive Bladder Cancer
08/33
08/33
NCT02890758: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Completed
1
14
US
Natural Killer (NK) Cells, ALT803, Cytokine
Brenda Cooper, MD
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
06/21
02/23
NCT04385849: Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19

Terminated
1
1
US
N-803, Saline
ImmunityBio, Inc.
COVID-19
07/20
07/20
NCT04290546: CIML NK Cell in Head & Neck Cancer

Completed
1
11
US
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, cytokine induced memory-like natural killer, Ipilimumab, CTLA-4 inhibitor, Cetuximab, EGFR inhibitor
Dana-Farber Cancer Institute, Altor BioScience, Bristol-Myers Squibb, Miltenyi Biomedicine GmbH
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
09/24
12/24
NCT06040918: Single Center Study Of N-803 Stimulation On Expansion, Enrichment, Proliferation Of Natural Killer Cells Collected By Apheresis

Completed
1
10
US
N-803
ImmunityBio, Inc.
Healthy Subjects
09/24
09/24
QUILT-3.076, NCT04898543: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
50
US
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
ImmunityBio, Inc.
Metastatic Solid Tumor
05/25
05/25
NCT06318871: Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma

Recruiting
1
10
US
Cytokine Induced Memory-like Natural Killer (CIML NK) Cells, NK Cells, Interleukin-2 (IL-2)
Dana-Farber Cancer Institute, Kidney Cancer Association
Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma, Chromophobe Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
12/25
05/30
NCT05618925: Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting
1
20
US
N803, Anktiva, CD19t-haNK suspension, Cyclophosphamide, Cytoxan, Fludarabine, Fludara, Rituximab, Rituxan
ImmunityBio, Inc.
Non Hodgkin's Lymphoma Refractory/Relapsed
03/26
03/27
NCT06321484: Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Recruiting
1
18
US
Cytokine-Induced Memory-like Natural Killer Cells, CIML NK Cells, Interleukin 2
Dana-Farber Cancer Institute, ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer, Ovarian Carcinoma, Ovarian Carcinoma, Recurrent
11/26
10/31
RV582, NCT05769569: Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission

Withdrawn
1
35
RoW
VRC07-523LS, VRC-HIVMAB075-00-AB, PGDM1400LS, N-803, Ad26.Mos4.HIV, MVA-BN-HIV, A244d11 gp120, ALFQ, Antiretroviral Therapy (ART)
Henry M. Jackson Foundation for the Advancement of Military Medicine, US Military HIV Research Program, Janssen Vaccines & Prevention B.V.
HIV-1-infection
07/25
07/25
CARMEN-803, NCT07049432: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Not yet recruiting
1
13
US
N803
University of Utah, ImmunityBio, Inc.
B-cell Non Hodgkin Lymphoma
09/28
09/29
NCT04340596: Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

Active, not recruiting
1
118
US
N-803 (IL-15 Superagonist), VRC07-523LS, 10-1074
National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, ImmunityBio, Inc.
HIV Infection
06/26
12/26
NCT05245292: 3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Active, not recruiting
1
28
US
3BNC117-LS, broadly neutralizing antibody, monoclonal antibody, 10-1074-LS, N803, IL-15 superagonist complex
Rockefeller University, National Institute of Allergy and Infectious Diseases (NIAID), Weill Medical College of Cornell University, University of Pennsylvania
Human Immunodeficiency Virus
12/25
12/25
NCT06956547: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

Available
N/A
US
nogapendekin-alfa inbakicept, NAI, N-803
ImmunityBio, Inc.
Lymphopenia
 
 
YE-NEO 001 / ImmunityBio
QUILT-2.025, NCT03552718: NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

Active, not recruiting
1
16
US
YE-NEO-001, YE-NEO-001 Injectable Suspension
NantBioScience, Inc.
Colorectal Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Pancreatic Cancer, Liver Cancer
07/25
12/25
PD-L1.t-haNK / ImmunityBio
QUILT 3.064, NCT04050709: QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Active, not recruiting
1
16
US
PD-L1 t-haNK
ImmunityBio, Inc.
Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor
10/24
12/24
HER2 t-haNK / ImmunityBio
CAR2BRAIN, NCT03383978: Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

Active, not recruiting
1
42
Europe
NK-92/5.28.z, Ezabenlimab
Johann Wolfgang Goethe University Hospital, DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH, Georg-Speyer-Haus, LOEWE Center Frankfurt Cancer Institute, German Cancer Research Center
Glioblastoma
12/25
06/26
bone marrow-derived mesenchymal stem cells / Be The Match BioTherapies, ImmunityBio
NCT04397796: Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation

Terminated
1
4
US
BM-Allo.MSC, Placebo
ImmunityBio, Inc.
COVID
09/20
09/20
Ad5-Covid-S/N / ImmunityBio
NCT06022224: A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

Terminated
2/3
35
US
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
ImmunityBio, Inc.
COVID-19
06/22
07/23
NCT04591717: COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers

Completed
1b
34
US
hAd5-S-Fusion+N-ETSD vaccine
ImmunityBio, Inc.
COVID-19
04/22
01/23
NCT04732468: COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA

Terminated
1
28
US
hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
ImmunityBio, Inc.
Covid19
07/22
01/23
NCT04710303: COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults

Completed
1
41
RoW
hAd5-S-Fusion+N-ETSD vaccine
ImmunityBio, Inc.
Covid19
08/22
08/22
CD19.t-haNK / ImmunityBio
NCT06334991: Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma

Recruiting
1
10
RoW
CD19 t-haNK, Rituximab
ImmunityBio, Inc.
Non-Hodgkin Lymphoma Refractory/ Relapsed
03/26
03/27
HCW9218 / HCW Biologics, ImmunityBio
NCT05145569: Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Withdrawn
2
33
NA
Carboplatin AUC 5 and paclitaxel, Carbo/Taxol, HCW9218
Haider Mahdi, HCW Biologics
Ovarian Cancer
05/26
01/28
NCT05304936: HCW9218 for Advanced Pancreatic Cancer

Active, not recruiting
1/2
60
US
HCW9218
ImmunityBio, Inc.
Advanced Pancreatic Carcinoma
01/25
02/25
NCT05322408: HCW9218 in Select Advanced Solid Tumors

Active, not recruiting
1
18
US
HCW9218, Monotherapy
Masonic Cancer Center, University of Minnesota
Solid Tumor
01/25
02/26
AAHI-SC2 Vaccine / ImmunityBio
NCT05370040: THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines

Terminated
1/2
60
RoW
AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine
ImmunityBio, Inc.
COVID-19
03/24
03/24
AAHI-SC3 Vaccine / ImmunityBio
No trials found
N-812 / ImmunityBio
No trials found

Download Options